Flotufolastat F-18

DB17851ApprovedInvestigationalSmall moleculeRadioactive Diagnostic Agent

Flotufolastat F-18 is a radiopharmaceutical diagnostic agent used in PET imaging to visualize PSMA-positive lesions in men with prostate cancer with suspected metastasis or recurrence. Flotufolastat F-18 (18F-rhPSMA-7.3) is an 18F-labeled ligand that targets the prostate-specific membrane antigen (PSMA).

Mechanism: Flotufolastat F-18 binds to the prostate-specific membrane antigen (PSMA) (IC50 = 4.4 nM) expressed on cells, including prostate cancer cells. The fluorine-18 group in flotufolastat F-18 is a ß+ emitting radionuclide that can be detected using positron emission tomography (PET). Since prostate cancer cells overexpress PSMA and flotufolastat F-18 is internalized by cells, this radioactive agent can be used for the diagnostic imaging of prostate cancer patients. Compared to morphologic imaging, such as computerized tomography (CT) scans and magnetic resonance imaging (MRI), the use of PET targeting PSMA is a superior technique for the localization of recurrent disease or primary node (N) staging.
Curator reviewed · 2 references
Primary indication: Flotufolastat F-18 is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or suspected recurrence based...Curator reviewed · 2 structured indications
Formula / weight: C₆₃H₉₉FN₁₂O₂₅Si · 1470.63 g/mol (avg)
First approval: United States, 2023
Also known as: (18F)-rhPSMA-7.3 · 18F-rhPSMA-7.3 · 18FrhPSMA-7.3 · F-18-rhPSMA-7.3 · Flotufolastat (18F)
Brand names: Posluma

Resolves to

Compound

UNII811W19E3OLCAS2639294-14-5ChEMBLCHEMBL5314558ChEBI229648PubChem154572844

Clinical / RWD

RxNorm2637946ATCV09IX18

Structure

InChIKeyQMGJNAVROCDAIW-MQNQVPOESA-NSMILES

CC(C)(C)[Si]([18F])(C1=CC=C(C=C1)C(=O)NC[C@@H](NC(=O)CC[C@H](N1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1)C(O)=O)C(=O)N[C@H](CCCCNC(=O)CCC(=O)NCCC[C@@H](NC(=O)CC[C@H](NC(=O)N[C@@H](CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C(O)=O)C(C)(C)C

Targets

Q04609FOLH1

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

11Drug interactionsStructured to mechanism, not free text

17Clinical trialsPhase, status and sponsor resolved per trial

2Structured indicationsCondition, population, route and combination as fields, not prose

1Marketed productAcross 1 country and 1 labeller

1ATC codeIncluding every combination product, plus 9 drug categories

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Flotufolastat F-18, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account